الخميس 10 محرم 1448هـ
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa
| عنوان الدراسة | داعم الدراسة | حالة الدراسة | دواء الدراسة | مرحلة الدراسة | رقم بروتوكول الدراسة | موقع الدراسة |
|---|---|---|---|---|---|---|
| ChaRactErization of patients following aCute venous thrOmboembolism (VTE) and assessment of safety and effectiveness of dabigatran etexilate (DE) in the tReatment and secondarY prevention of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) in comparison to vitamin K antagonist (VKA) in routine clinical practice - RE-COVERY DVT/PE | Boehringer Ingelheim | Ongoing | Dabigatran etexilate | 4 | 1160.188 | King Salman Bin AbdulAziz Hospital |
| Forxiga (dapagliflozin) Post Authorization Safety Study | AstraZeneca | Ongoing | Forxiga | 4 | D1690R0003 | King Khalid University Hospital (Riyadh), Taibah University College of Medicine, Dr. Sulaiman Al-Habib Medical Group (Riyadh), Specialized Medical Center (Riyadh), International Medical Center (Jeddah), Dallah Hospital (Riyadh), King Abdulaziz University Hospital (Jeddah) |
| A Multicenter, prospective, non-interventional study to assess Adherence to treatment for patIeNts with Relapsing Multiple Sclerosis (RMS) who are prescribed subcutaneous (sc) interferon beta-1a | Merck Serono | Ongoing | Interferon Beta-1 a (Rebif) | 4 | MS200136_0 | King Fahad Specialist Hospital (Dammam), King Khalid University Hospital (Riyadh), King Fahad University Hospital (Al-Khobar), King Faisal Specialist Hospital and Research Center (Jeddah) |
| "CAIN457A3404-REALIAA non-interventional, prospective 12-months study to characterize the REAL-life effectiveness and treatment patterns of SecukInumab and current standard of care inpatient with chronic plaque psoriAsis eligible for systemic treatment in the Asia-Pacific and Middle East regions" | Novartis | Ongoing | Cosyntex | 4 | IN457A3404 | King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah) |
| Does the Addition of Proton Pump Inhibitors to Continuous Enteral Feeding Provide Added Protection Against Upper GI Bleeding in Acutely Ill Patients | KAIMRC | Ongoing | Esmoprozol | 4 | RC15/079 | King Abdulaziz Medical City NG (Riyadh) |
| Real World retrospective study of effectiveness and safety of Gilenya (FINgOlimod) in relapsing remitting Multiple Sclerosis in the Middle East and North Africa (FINOMENA) | Novartis | Ongoing | Fingolimod | 4 | TY720DAE01 | King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Hospital (Jeddah), King Abdulaziz Hospital Oncology Center, King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh), Al-Noor Specialist Hospital (Makkah), Hira Hospital (Makkah), King Fahad Specialist Hospital (Dammam), Dr. Erfan & Bagedo General Hospital (Jeddah) |
| A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis | Novartis | Ongoing | ofatumumab | 3 | COMB157G2301 | King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Randomized, Open-label Trial of Paritaprevir Plus Ritonavir Plus Ombitasvir in the Treatment of HCV Genotype 4 Infected Patients with Stage 4-5 Chronic Kidney Disease | Abbvie Biopharmaceuticals GmbH / KSU Liver Disease Research Center | Ongoing | ombitasvir \ paritaprevir \ ritonavir | 3 | Version 1.3.1 | King Abdulaziz Medical City NG (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Hospital (Jeddah) |
| "Open-label, multicenter, single arm, phase II study assessing treatment patient preference for new deferasirox formulation (film-coated tablet) compared to the reference deferasirox dispersible tablet formulation" | Novartis | Ongoing | deferasirox | 2 | CICL670FIC05 | King Abdulaziz University Hospital (Jeddah), Hereditary Blood Disease Center (al ahsa), King Abdulaziz Medical City NG (Riyadh) |
| International, randomized, open label study to compare the safety and efficacy of lixisenatide vs sulfonylurea on top of basal insulin treatment in Type 2 Diabetes Mellitus subjects who elect to fast during Ramadan | Sanofi | Terminated | Lixisenatide | 3 | LPS14410 | King Khalid University Hospital (Riyadh) |
تاريخ آخر تحديث: 08/05/2025 بتمام الساعة 03:17 مساء بتوقيت المملكة العربية السعودية
لم يتم تقديم أي تقييمات لهذه الصفحة بعد.
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.